Last update 19 Sep 2024

Medibiofarma SL

Holding Company|
2016|
Spain
|
www.medibiofarma.com

Overview

Basic Info

Introduction
Medibiofarma is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. They aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases.

Tags

Other Diseases
Neoplasms
Nervous System Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms3
Nervous System Diseases1
Immune System Diseases1
Top 5 Drug TypeCount
Small molecule drug4
Top 5 TargetCount
HDAC1 x HDAC21
PPARγ(Peroxisome proliferator-activated receptor γ)1
EP4(Prostanoid EP4 receptor)1

Related

5
Drugs associated with Medibiofarma SL
MBF-015
Target
HDAC1 x HDAC2
Mechanism
HDAC1 inhibitors [+1]
Active Org.
Medibiofarma SL
Originator Org.
Medibiofarma SL
Active Indication
Huntington Disease [+1]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
MBF-118
Target
PPARγ
Mechanism
PPARγ agonists
Active Org.
Medibiofarma SL
Originator Org.
Medibiofarma SL
Active Indication
Constriction, Pathologic [+3]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
MBF-362
Target
EP4
Mechanism
EP4 antagonists
Active Org.
Medibiofarma SL
Originator Org.
Medibiofarma SL
Active Indication
Solid tumor [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
6
Clinical Trials associated with Medibiofarma SL
CTIS2023-505241-10-00 / Recruiting
A phase IIa, open label, single centre study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally dosed MBF-015 in Huntington's disease patients - MBF-015CT-02
NCT06469853 / RecruitingPhase 2
A Phase IIa, Open Label, Single Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Dosed MBF-015 in Huntington's Disease Patients
NCT05940558 / RecruitingPhase 2
A Phase IIa, Open Label, Single-centre Study to Assess the Initial Antifibrotic Efficacy, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of MBF-118 in Crohn's Disease Patients With Stenosis
100 Clinical Results associated with Medibiofarma SL
Login to view more data
0 Patents (Medical) associated with Medibiofarma SL
Login to view more data
100 Deals associated with Medibiofarma SL
Login to view more data
100 Translational Medicine associated with Medibiofarma SL
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Sep 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
1
Phase 1 Clinical
Phase 2 Clinical
2
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
MBF-118
 ( PPARγ )		Crohn Disease
More
Phase 2
MBF-015
 ( HDAC1 x HDAC2 )		Huntington Disease
More
Phase 2
MBF-362
 ( EP4 )		Solid tumor
More
Phase 1
MBF-132
Fibrosis
More
Discovery
MBF-251
 ( EP2 x EP4 )		Neoplasms
More
Discontinued
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free